News Conference News ACC 2026 Financial Support After Hospital Discharge Boosts HFrEF Outcomes: FUND-HF L.A. McKeown April 08, 2026
News Conference News ACC 2026 DIG-RHD: Digoxin Effective in Rheumatic Heart Disease Michael O'Riordan April 06, 2026
News Conference News ACC 2026 SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients Michael O'Riordan March 30, 2026
News Conference News ACC 2025 FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints L.A. McKeown April 03, 2025
News Conference News ACC 2024 HUDDLE Up! High BP and Cardiac Changes Prevalent in Retired NFL Players Michael O'Riordan April 15, 2024
News Conference News ACC 2024 Vaping Linked to Higher Risk of HFpEF, NIH Data Show L.A. McKeown April 12, 2024
News Conference News ACC 2024 Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI Michael O'Riordan April 07, 2024
News Conference News ACC 2024 STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed L.A. McKeown April 06, 2024
News Conference News ACC 2024 Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It Michael O'Riordan March 27, 2024
News Conference News ACC 2023 IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF L.A. McKeown March 14, 2023
News Conference News ACC 2023 AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup L.A. McKeown March 09, 2023
News Conference News ACC 2023 Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2 Michael O'Riordan March 09, 2023
News Conference News ACC 2023 BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF L.A. McKeown March 06, 2023
News Conference News ACC 2022 DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF L.A. McKeown April 08, 2022
News Conference News ACC 2022 QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis L.A. McKeown April 07, 2022
News Conference News ACC 2022 SODIUM-HF: No Impact of Tighter Dietary Salt Restriction on Death or Hospitalization L.A. McKeown April 02, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Conference News ACC 2021 Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF Michael O'Riordan May 25, 2021
News Conference News ACC 2021 Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF Yael L. Maxwell May 16, 2021